Drug Profile
IG 003
Alternative Names: IG-003Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Infusion)
- 31 Dec 2013 Preclinical trials in Solid tumours in USA (IV)